ReviewGenes & development2025
Transcription quality control at the promoter-proximal checkpoint.
Review in Genes & development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Mechanisms of transcription termination across the coding and noncoding loci of the genome.Nature reviews. Molecular cell biology · 2026Review
- ELOF1 is a core component of the promoter-proximal paused RNA polymerase II complex.bioRxiv : the preprint server for biology · 2026Article
- Coordinating mRNA maturation: The U1 relay model.Molecular cell · 2026Review
- Promoter proximal pausing of RNA polymerase across evolution.Nature structural & molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcription of protein-coding genes by RNA polymerase II involves a characteristic pausing event downstream from transcription start sites. Such promoter-proximal pausing likely represents a transcription checkpoint, which ensures proper assembly of a fully functional RNAPII elongation complex that is capable of transcribing through the chromatin environment, with correctly modified nascent pre-mRNA. Failure to negotiate this promoter-proximal checkpoint results in termination of transcription and removal of RNAPII from the DNA. This review summarizes current knowledge on the mechanisms that regulate promoter-proximal pausing, maturation of the elongation complex, and the decision of whether to license RNAPII for elongation or prematurely terminate transcription.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.